Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study

PURPOSE: To determine if maintenance rituximab (MR) after standard chemotherapy improves progression-free survival (PFS) in advanced-stage indolent lymphoma. PATIENTS AND METHODS: Patients with stage III-IV indolent lymphoma with responding or stable disease after cyclophosphamide, vincristine, and...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Hochster, Howard, Weller, Edie, Gascoyne, Randy D., Habermann, Thomas M., Gordon, Leo I., Ryan, Theresa, Zhang, Lijun, Colocci, Natalia, Frankel, Stanley, Horning, Sandra J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2009
Soggetti:
Original Reports
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2668968/
https://ncbi.nlm.nih.gov/pubmed/19255334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.17.1561
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi